文献速递免疫规划

四价登革热候选疫苗皮内接种安全性与免疫原性的1期研究

A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
PubMed 文献 · Vaccine · 2018-05-19

在美国两个中心对18-45岁无登革热疫苗接种或病史的健康人开展1b期研究,评估早期低剂量四价登革热候选疫苗(基于减毒2型骨架)经PharmaJet注射器或针筒皮内接种的安全性与免疫原性;因世界卫生组织对疫苗储存条件的预认证指南变化而提前停止入组,共入组67人,65人完成计划程序;所有方案均诱导中和抗体,1、2型滴度高于3、4型,两剂次未见一致性增强。

要点

  • 所有疫苗接种方案均诱导了针对登革热病毒的中和抗体。
  • 针对1型和2型的中和抗体滴度高于3型和4型。
  • 同时注射两剂低剂量四价登革热候选疫苗可能提高1型和2型血清阳转率并增加2型抗体滴度。

核心结论

  • 同时注射两剂低剂量四价登革热候选疫苗显示出提高1型和2型血清阳转率及增加2型抗体滴度的潜力。
  • 经PharmaJet接种基础剂量低剂量四价登革热候选疫苗较针筒接种可诱导针对1、2、3型更快的血清阳转。

研究设计与样本

  • 在日本武田公司开展的1b期研究中,于美国两个中心纳入18-45岁无登革热疫苗接种史或疾病史的健康受试者。
  • 受试者在第0天接种一剂或两剂疫苗,第90天接种另一剂或安慰剂。
  • 中和抗体检测至第270天;安全性通过实验室检测及日记卡记录征集性和非征集性不良事件评估。

主要发现

  • 因世界卫生组织关于新疫苗预认证指南中储存条件的变化,研究提前停止入组,但已入组67名受试者进入四个治疗组。
  • 65名受试者完成了计划程序;未观察到安全性信号或严重不良事件。
  • 所有疫苗接种方案均诱导了中和抗体;针对1型和2型的中和抗体滴度高于针对3型和4型的滴度。
  • 两剂次同时或间隔90天接种未见应答的一致性增加。

临床怎么用

  • 同时注射两剂低剂量四价登革热候选疫苗显示出提高1型和2型血清阳转率及增加2型抗体滴度的潜力。
  • 经PharmaJet接种基础剂量低剂量四价登革热候选疫苗较针筒接种可诱导针对1、2、3型更快的血清阳转。

局限性

  • 因世界卫生组织预认证指南关于储存条件的变化,研究提前停止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet®), or needle-syringe. METHODS: The study was performed in two centers in the US, in healthy 18-45 year old subjects with no history of dengue vaccination or disease. One or two vaccine doses were given on Day 0, and another dose or placebo on Day 90. Neutralizing antibodies were measured up to Day 270; safety was assessed as laboratory measurements and solicited and unsolicited adverse events on diary cards. RESULTS: Changes in World Health Organization prequalification guidance for new vaccines concerning storage conditions favored the use of lyophilized preparations, and led to the early cessation of enrolment, but not before 67 subjects were enrolled in four treatment groups. Sixty-five subjects completed the planned schedule. There were no safety signals or serious adverse events. All vaccination regimens elicited neutralizing antibodies. Titers of neutralizing antibodies against serotypes 1 and 2 were higher than those against serotypes 3 and 4. There were no consistent increases in responses with two doses given either concomitantly or 90 days apart. CONCLUSIONS: Simultaneous injection of two LD-TDV doses was shown to have the potential to improve seroconversion rates to serotypes 1 and 2, and to increase serotype 2 antibody titers. A primary dose of LD-TDV administered by PharmaJet was shown to induce more rapid seroconversion to serotypes 1, 2, and 3 compared with administration by needle-syringe (ClinicalTrials.gov: NCT01765426).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jackson LA, Rupp R, Papadimitriou A, et al. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Vaccine. 2018. PMID: 29789238. doi:10.1016/j.vaccine.2018.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。